Related Experiment Video

Updated: Apr 28, 2026

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression
07:53

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression

Published on: March 17, 2020

6.5K

Ethoxysanguinarine Induces Inhibitory Effects and Downregulates CIP2A in Lung Cancer Cells

Zi Liu1, Liang Ma2, Zhe-Sheng Wen3

  • 1Division of Molecular Carcinogenesis and Targeted Therapy for Cancer, State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Chinese Academy of Sciences , Beijing 100101, China ; University of Chinese Academy of Sciences , Beijing 100049, China.

ACS Medicinal Chemistry Letters
|June 6, 2014
PubMed

Insights

Overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) indicates poor lung cancer prognosis. The natural compound ethoxysanguinarine (ESG) inhibits cancer cell growth by downregulating CIP2A.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein.
  • CIP2A stabilizes c-Myc, promoting cell proliferation and transformation.
  • CIP2A is overexpressed in many primary tumors, making it a therapeutic target.

Purpose of the Study:

  • To investigate the prognostic value of CIP2A in lung cancer.
  • To evaluate the potential of ethoxysanguinarine (ESG) as a CIP2A inhibitor.

Main Methods:

  • Assessed CIP2A expression in lung cancer tissues.
  • Treated lung cancer cells with ESG.
  • Measured downstream signaling molecules (c-Myc, pAkt) and apoptosis.
  • Evaluated ESG's effect in combination with cisplatin.

Main Results:

  • CIP2A overexpression correlates with poor lung cancer prognosis.
  • ESG downregulates CIP2A, c-Myc, and pAkt, and increases PP2A activity.
  • ESG inhibits lung cancer cell proliferation and induces apoptosis.
  • ESG enhances cisplatin's efficacy against lung cancer cells.

Conclusions:

  • CIP2A is a prognostic biomarker for lung cancer.
  • ESG demonstrates therapeutic potential as a CIP2A inhibitor for lung cancer treatment.
  • ESG warrants further investigation as a lead compound for novel anticancer therapies.
Keywords:
CIP2AEthoxysanguinarineapoptosiscell proliferationlung cancer

More Related Videos

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy15:55

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy

Published on: June 21, 2013

10.1K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

6.8K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K